Skip to main content
. 2022 Dec 23;12(12):e063650. doi: 10.1136/bmjopen-2022-063650

Table 1.

Inclusion/exclusion criteria

Inclusion criteria Exclusion criteria
At least 18 years old Evidence of inflammatory joint pain, enthesitis and/or dactylitis
Willing and able to provide informed consent Current systemic immunosuppressive medication use (ie, methotrexate, apremilast) at time of enrolment or biological use ever
Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants) Mid-to-high positive rheumatoid factor and/or anti-citrullinated protein antibodies (greater than 2 times the upper limit of normal)
Psoriasis body surface area greater than or equal to 3% Current active malignancy
Positive imaging findings on ultrasound defined as Rochester Modified-PsASon score >3.36 History of symptomatic polyarticular osteoarthritis (OA) or other joint conditions (such as rheumatoid arthritis, gout) that may impair the ability to assess for psoriatic arthritis development
Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infections and untreated latent tuberculosis
Known hypersensitivity to the study agent